<DOC>
	<DOCNO>NCT01996969</DOCNO>
	<brief_summary>Regorafenib valuable treatment option metastatic colorectal cancer patient progress prior standard treatment . Prior progression-free survival data suggest could distinct subgroup patient may benefit regorafenib . The aim study identify predictive biomarker regorafenib term efficacy .</brief_summary>
	<brief_title>Identification Predictive Biomarker Regorafenib Refractory Colorectal Cancer</brief_title>
	<detailed_description>Regorafenib multi-tyrosine kinase inhibitor show increase survival metastatic colorectal cancer patient progress prior standard treatment . Progression-free survival data suggest could distinct subgroup patient may benefit regorafenib . Therefore , would important identify predictive biomarker efficacy regorafenib . Considering regorafenib multi-tyrosine kinase inhibitor , comprehensive approach require discover predictive biomarker . NGS-based sequencing allow generate large amount data regard multiple gene multiple genetic alteration within single experiment . Also , require less amount DNA tissue cost compare currently use individual gene test technique direct sequence FISH . Moreover , superior sensitivity Sanger sequencing obtain increase coverage depth , especially case low tumor purity . Wide range gene target regorafenib gene major oncogenic pathway colorectal cancer influence regorafenib efficiently assess use NGS-based sequencing . The aim study identify predictive biomarker efficacy regorafeinib metastatic , refractory colorectal cancer patient use NGS technology .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Signed informed consent obtain studyspecific procedure . 2 . Age ≥ 20 3 . Pathologically confirm metastatic adenocarcinoma colon rectum 4 . Failure standard therapy , must include fluoropyrimidine , oxaliplatin , irinotecan . Failure define progression within 3 month follow last administration therapy . Patients withdrawn standard treatment due unacceptable toxicity warrant discontinuation treatment preclude retreatment agent progression disease also allow study . Patients treat oxaliplatin adjuvant setting progress within 6 month completion adjuvant therapy regard failure oxaliplatin . Patients may may receive bevacizumab cetuximab . 5 . Measurable nonmeasurable disease accord RECIST criterion , version 1.1 . 6 . Adequate tissue gene sequencing ( surgical FFPE specimen freshfrozen biopsy specimen ) 7 . ECOG PS 0 1 8 . Life expectancy least 3 month 9 . Adequate bonemarrow , liver , renal function assess follow laboratory requirement conduct within 14 day start study treatment Total bilirubin ≤1.5 × ULN Alanine aminotransferase aspartate aminotransferase ≤2 × ULN ( ≤5 × ULN patient liver involvement cancer ) Amylase lipase ≤1.5 × ULN Serum creatinine ≤1.5 × ULN Glomerular filtration rate ≥30 ml/min/1.73 m2 accord Modified Diet Renal Disease abbreviate formula International normalise ratio ( INR ) partial thromboplastin time ( PTT ) ≤1.5 × ULN . Subjects therapeutically treat agent warfarin heparin allow participate provide prior evidence underlie abnormality coagulation parameter exist . Platelet count ≥100,000/mm3 , haemoglobin &gt; 9 g/dl , absolute neutrophil count &gt; 1,500/mm3 Alkaline phosphatase limit ≤2.5 × ULN ( ≤5 × ULN patient liver involvement cancer ) 1 . Prior treatment regorafenib 2 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day start study medication 3 . Pregnancy breastfeed . Women childbearing potential must negative pregnancy test perform maximum 7 day start treatment 4 . Congestive heart failure NYHA class 2 bad 5 . Unstable angina , newonset angina ( begin within last 3 month ) . Myocardial infarction le 6 month start study drug 6 . Cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) 7 . Uncontrolled hypertension ( systolic blood pressure &gt; 150 mmHg diastolic &gt; 90 mmHg despite optimal medical management ) 8 . Arterial venous thrombotic embolic event within 6 month start study medication 9 . Ongoing infection high NCICTCAE v4.0 grade 2 10 . Known history HIV infection 11 . Active hepatitis B C virus infection 12 . Seizure disorder require medication 13 . Symptomatic metastatic brain meningeal tumor 14 . History organ allograft 15 . Nonhealing wound , ulcer , bone fracture 16 . Interstitial lung disease ongoing sign symptoms time inform consent 17 . Persistent proteinuria NCICTCAE v4.0 grade 3 high 18 . Inability swallow oral medication 19 . Any malabsorption condition 20 . Unresolved toxicity high NCICTCAE v4.0 grade 1 attributed prior therapy/procedure , exclude alopecia oxaliplatininduced neurotoxicity grade 2 less</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>refractory</keyword>
	<keyword>regorafenib</keyword>
	<keyword>biomarker</keyword>
	<keyword>gene sequence</keyword>
</DOC>